

Biognosys and FGCZ announce collaboration on SpectroDive™ PRM testing

March 7, 2014 – Zurich-Schlieren (CH) – Biognosys AG, a Swiss Proteomics Company, and [Functional Genomics Center Zurich \(FGCZ\)](#), a state-of-the-art research and training facility of the University of Zurich and ETH Zurich, announced today the collaboration on a large-scale testing of SpectroDive™ software for Multiple and Parallel Reaction Monitoring (MRM and PRM, respectively).

MRM is a well-established method for targeted proteomics and is primarily performed on triple quadrupole mass spectrometers. PRM was introduced only recently and is performed on the latest generation of high-resolution mass spectrometric instruments. Both methods allow for highly specific and sensitive quantification of proteins from nearly any biological sample.

SpectroDive™ is Biognosys' proprietary software for automated MS method set-up, signal processing and data analysis. It is an integral part of [MRM Assay Panels](#) (e.g. PlasmaDeepDive™ 100) that are offered by Biognosys as a plug-and-play solution for multiplexed protein quantification.

Compared to classical MRM, PRM relies on high mass precision data that allows the removal of interfering signals providing additional advantages for peptide detection and quantification. Before the official release, Biognosys and FGCZ initiated a collaboration in order to test the software on a broader range of different experiments and further develop the PRM method. The FGCZ was chosen due to its scientific excellence, diversity of instrument set-ups and experience with large-scale experiments.

Biognosys currently offers its MRM and PRM capabilities as a service and standardized off-the-shelf MRM Assay Panels, while the PRM Assay Panels are planned to be made commercially available in the near future.

About Biognosys

Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.

About FGCZ

The Functional Genomics Center Zurich (FGCZ) is a joint state-of-the-art research and training facility of the ETH Zurich and the University of Zurich. With latest technologies and expert support for Omics research, the FGCZ carries out research projects and technology development in collaboration with the Zurich Life Science research community.

Contact: info@biognosys.ch, www.biognosys.ch